Reduction of sympathetic outflow by central administration of L-DOPA, dopamine and norepinephrine.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002552:Cerebral Ventricles / Q000187:drug effects; D002712:Chlorides; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004298:Dopamine / Q000494:pharmacology*; D004562:Electrocardiography; D004566:Electrodes; D004952:Esters / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008297:Male; D009409:Nerve Crush; D009638:Norepinephrine / Q000494:pharmacology*; D051381:Rats; D013564:Sympathetic Nervous System / Q000187:drug effects*; D014443:Tyrosine / Q000494:pharmacology
D002712:Chlorides; D004952:Esters; D000804:Angiotensin II; D014443:Tyrosine; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine